Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset? | Zendy

Patricia Corzo | Zendy; A. Pros | Zendy; Juana MartínezLlorens | Zendy; Luis Molina | Zendy; Stephanie Ling | Zendy; Eva Balcells | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?

Author(s) -

Patricia Corzo,

A. Pros,

Juana MartínezLlorens,

Luis Molina,

Stephanie Ling,

Eva Balcells

Publication year - 2018

Publication title -

clinical rheumatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.835

H-Index - 82

eISSN - 1434-9949

pISSN - 0770-3198

DOI - 10.1007/s10067-018-4342-5

Subject(s) - dlco , medicine , cardiology , diffusing capacity , rheumatology , lung , lung function

Diffusing capacity for carbon monoxide (DLco) reduction is the first detectable pulmonary functional test (PFT) change in systemic sclerosis (SSc)-related pulmonary complications. reduction in patients without cardiopulmonary alterations has also been observed; a good characterisation of these patients is lacking. The objective of this study is to describe the characteristics of SSc patients with isolated DLco reduction and compare these patients to SSc patients with DLco reduction with a known cause.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research